Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs GLENMARK PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON GLENMARK PHARMA BIOCON /
GLENMARK PHARMA
 
P/E (TTM) x 35.8 13.5 265.8% View Chart
P/BV x 4.0 1.3 300.2% View Chart
Dividend Yield % 0.2 0.6 31.2%  

Financials

 BIOCON    GLENMARK PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-22
GLENMARK PHARMA
Mar-22
BIOCON /
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs424691 61.4%   
Low Rs315416 75.8%   
Sales per share (Unadj.) Rs68.2436.1 15.6%  
Earnings per share (Unadj.) Rs8.235.2 23.1%  
Cash flow per share (Unadj.) Rs14.952.5 28.5%  
Dividends per share (Unadj.) Rs0.502.50 20.0%  
Avg Dividend yield %0.10.5 29.9%  
Book value per share (Unadj.) Rs68.5321.4 21.3%  
Shares outstanding (eoy) m1,200.60282.17 425.5%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x5.41.3 427.4%   
Avg P/E ratio x45.315.7 288.7%  
P/CF ratio (eoy) x24.710.5 234.7%  
Price / Book Value ratio x5.41.7 313.3%  
Dividend payout %6.17.1 86.4%   
Avg Mkt Cap Rs m443,622156,067 284.3%   
No. of employees `000NANA-   
Total wages/salary Rs m18,80124,474 76.8%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m81,840123,049 66.5%  
Other income Rs m6,8911,667 413.4%   
Total revenues Rs m88,731124,716 71.1%   
Gross profit Rs m13,82720,594 67.1%  
Depreciation Rs m8,1424,867 167.3%   
Interest Rs m6762,981 22.7%   
Profit before tax Rs m11,90014,412 82.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1154,476 47.3%   
Profit after tax Rs m9,7859,936 98.5%  
Gross profit margin %16.916.7 100.9%  
Effective tax rate %17.831.1 57.2%   
Net profit margin %12.08.1 148.1%  
BALANCE SHEET DATA
Current assets Rs m83,82382,823 101.2%   
Current liabilities Rs m38,28046,894 81.6%   
Net working cap to sales %55.629.2 190.6%  
Current ratio x2.21.8 124.0%  
Inventory Days Days1016 1,558.6%  
Debtors Days Days9292 99.8%  
Net fixed assets Rs m117,18471,148 164.7%   
Share capital Rs m6,003282 2,127.4%   
"Free" reserves Rs m76,28190,421 84.4%   
Net worth Rs m82,28490,703 90.7%   
Long term debt Rs m39,98525,717 155.5%   
Total assets Rs m201,007153,972 130.5%  
Interest coverage x18.65.8 318.8%   
Debt to equity ratio x0.50.3 171.4%  
Sales to assets ratio x0.40.8 50.9%   
Return on assets %5.28.4 62.0%  
Return on equity %11.911.0 108.6%  
Return on capital %10.314.9 68.8%  
Exports to sales %00-   
Imports to sales %7.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m6,360NA-   
Fx inflow Rs m8,88532,142 27.6%   
Fx outflow Rs m6,36013,482 47.2%   
Net fx Rs m2,52518,660 13.5%   
CASH FLOW
From Operations Rs m11,76611,087 106.1%  
From Investments Rs m-16,991-3,333 509.8%  
From Financial Activity Rs m2,421-5,205 -46.5%  
Net Cashflow Rs m-2,4332,724 -89.3%  

Share Holding

Indian Promoters % 39.7 46.7 85.0%  
Foreign collaborators % 21.0 0.0 -  
Indian inst/Mut Fund % 23.6 34.1 69.1%  
FIIs % 15.8 23.1 68.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.4 53.4 73.8%  
Shareholders   369,816 313,540 117.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   SUN PHARMA    DR. REDDYS LAB    CIPLA    LUPIN    AUROBINDO PHARMA    


More on Biocon vs Glenmark Pharma

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

Biocon vs Glenmark Pharma Share Price Performance

Period Biocon Glenmark Pharma S&P BSE HEALTHCARE
1-Day -0.04% 2.06% -0.89%
1-Month -1.17% 2.33% -1.85%
1-Year -28.05% -15.20% -6.83%
3-Year CAGR -1.64% 9.52% 20.56%
5-Year CAGR -11.98% -4.29% 10.73%

* Compound Annual Growth Rate

Here are more details on the Biocon share price and the Glenmark Pharma share price.

Moving on to shareholding structures...

The promoters of Biocon hold a 60.6% stake in the company. In case of Glenmark Pharma the stake stands at 46.7%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Biocon and the shareholding pattern of Glenmark Pharma.

Finally, a word on dividends...

In the most recent financial year, Biocon paid a dividend of Rs 0.5 per share. This amounted to a Dividend Payout ratio of 6.1%.

Glenmark Pharma paid Rs 2.5, and its dividend payout ratio stood at 7.1%.

You may visit here to review the dividend history of Biocon, and the dividend history of Glenmark Pharma.

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Trades Higher | Capital Goods, Energy Stocks Witness Buying | Axis Bank and M&M Among Top Gainers(10:30 am)

Asian share markets are trading on a mixed note today as growing fears of an economic slowdown and worries over the pace of the Federal Reserve's interest rate hikes weighed on sentiment.